Hims & Hers Health stock drops 5.44% as data breach impacts third-party platform

Traders Union
All News
Financial News
Hims & Hers Health drops 5.44% today

Highlights

Hims & Hers faces legal scrutiny and class action risk after terminating its Novo Nordisk partnership and reporting a customer data breach.
Despite launching a new weight loss membership featuring FDA-approved GLP-1 treatments, the company continues to experience revenue pressure and legal headwinds.
Shares remain under steady selling pressure, trading below major averages, with a likely price range of $17.50–$21.00 and downside risk prevailing.

Growing legal scrutiny as data breach and partnerships drive sentiment

On April 7, 2026, Hims & Hers Health reported a data breach on its third-party customer service platform that exposed certain customer names, contact details, and support request information, though medical records and provider communications were not affected. The company stated the incident is not expected to have a material impact on financial performance. Legal investigations and a securities fraud class action were recorded following the June 2025 termination of its partnership with Novo Nordisk over compounded medication practices, and in April 2026, Hims & Hers launched a weight loss membership with access to FDA-approved GLP-1 treatments online. These developments were accompanied by ongoing revenue pressures and legal scrutiny.

Momentum bias remains bearish as intraday volatility persists

Momentum remains weak, as MACD and ADX on D1 both indicate a sell bias, while RSI sits at 47.83 and CCI at –78.21, reflecting bearish to neutral territory with some oversold characteristics. Stoch RSI signals a potential oversold bounce, yet BBP at –0.21 confirms sellers continue to dominate intraday momentum. HIMS opened below the previous session's close (minor downside gap) and pushed sharply lower, closing near the low of today's range after a $1.10 or 5.44% decline, indicating high intraday volatility and persistent downside pressure following the open. The conflicting signals between some oscillators and momentum indicators highlight possible short-term relief, but confirm continued selling pressure in the current intraday tone.

Downside risk dominates as key levels cap upside scenarios

For the coming week, the expected price corridor is adjusted to $17.50 – $21.00 to reflect typical volatility and keep the range in line with current levels. The probability of a price increase is very low (less than 20%), making a further decline more likely based on the alignment of W1 MA-50, MACD, and RSI, all pointing to downside. Baseline scenario: price remains sideways within $17.50 – $21.00. Bullish scenario: a move above immediate resistance at $20.93 could target $21.00, but conviction is low, while a break below $19.00 risks extension toward the $17.50 level.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health Inc under sustained technical and fundamental pressure. Weak momentum, bearish price action, and recent legal issues weigh on sentiment. He believes the stock is likely to remain rangebound, with sellers in control unless $20.93 is regained decisively. "As long as HIMS stays below key resistance and uncertainty persists, I see no strong setup for bulls this week."

Earlier, analysts noted that Hims & Hers Health was experiencing persistent downside momentum and elevated risks due to ongoing legal and revenue headwinds. The latest developments—including the recent data breach announcement and continued technical weakness—further underscore the prevailing bearish bias, making a potential break below the $19.00 level a critical downside risk for the coming week.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.